Minimally invasive locoregional therapies have a growing role in the multidisciplinary
treatment of primary and metastatic breast cancer. Factors contributing to the expanding role …

Percutaneous image-guided locoregional therapies are emerging in the treatment of primary
and metastatic breast cancer. Cryoablation has emerged as the dominant ablative approach …

Emerging evidence regarding the effectiveness of locoregional therapies (LRTs) for breast
cancer has prompted investigation of the potential role of interventional radiology (IR) in the …

Background Locoregional therapy (LRT) in de novo metastatic disease is controversial with
inconsistent results from randomized control trials (RCTs). Methods RCTs comparing LRT …

Breast cancer has now overtaken lung cancer as the world's mostly commonly-diagnosed
cancer, according to statistics released by the International Agency for Research on Cancer …

Stage IV breast cancer, either de novo at presentation or secondary after a primary
diagnosis, is a heterogeneous disease. While patients with metastatic breast cancer are …

Locoregional management of breast cancer is founded on evidence generated over a vast
time period, much longer than the career span of many practicing physicians. Oncologists …

Metastatic breast cancer (MBC) at presentation (Stage IV) is a devastating diagnosis with a
poor prognosis and a 5-year overall survival rate not exceeding 20%. The treatment is …

Locoregional therapy for breast cancer seeks to achieve several goals. First and foremost, it
must provide long-term locoregional control, meaning survival without recurrence in the …

Guidelines for the locoregional treatment of primary breast cancer were last published by the
US National Institutes of Health in 1991. Since then, new surgical and radiotherapeutic …